C(=O)NCCCN1CCN(CC1)CCCNC(=O)[C@@H](N)CCCNC(N)=N](https://cdn.shopify.com/s/files/1/0389/1897/9723/products/M8719_1621504072.gif?v=1629706157)
Pay in 4 interest-free payments of $26.25 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Smiles: NC(=N)NCCC[C@H](N)C(=O)NCCCN1CCN(CC1)CCCNC(=O)[C@@H](N)CCCNC(N)=N
InChi: InChI=1S/C18H19N3O6/c22-13-8-7-12(16(25)20-13)21-17(26)10-4-3-5-11(15(10)18(21)27)19-9-2-1-6-14(23)24/h3-5
Karlsson JJ
Formula: C28H30N6O3
01-10 μM) blocks CK1ϵ-mediated PER3 nuclear localization mediated by CK1ϵ and suppresses PER2 degradation at 1 μM
Ruxolitinib (S) 05 trifluoroacetate Smiles: NC(=N)NCCC[C@H](N)C(=O)NCCCN1CCN(CC1)CCCNC(=O)[C@@H](N)CCCNC(N)=NS Ruxolitinib is a less active enantiomer of Ruxolitinib, a JAK1 2 inhibitor. S Ruxolitinib was initially developed to target the constitutive activation of the JAK STAT pathway. Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases that mediates signals from the receptors for various cytokines and growth factors that have a key role in haematopoiesis and immune function. Ruxolitinib maintains its anti JAK activity by competitive
US$ 124.87
US$ 23.00
US$ 39.24
US$ 212.50
US$ 55.00
US$ 16.00
US$ 149.99
US$ 14.99
US$ 175.89
US$ 35.68
US$ 112.50
US$ 99.90
US$ 150.00